Banpixan 2,5 mg and 5 mg Film-coated tablets
PDF Leaflet Revision Date: 22 July 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Prevention of VTE in elective hip or knee replacement surgery and prevention of stroke in NVAF.
Dosage (summary)
2.5 mg twice daily for VTE; 5 mg twice daily for NVAF.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly
Pregnancy & Breastfeeding
Not recommended during pregnancy; unknown if excreted in breast milk.
Key Drug Interactions
- Strong CYP3A4 and P-gp inhibitors
- Strong CYP3A4 and P-gp inducers
- Antiplatelet medicines
Contraindications
- Hypersensitivity to apixaban
- Active bleeding
- Severe renal disease
- Severe hepatic disease
- Antiphospholipid syndrome
Common side effects
- Anaemia
- Haemorrhage
- Nausea
- Contusion
Counselling Points
- Take with or without food
- Monitor for signs of bleeding
- Do not stop before surgery without consulting healthcare provider
Serious warnings
- Risk of bleeding
- No antidote for overdose
Important Disclaimer
The Banpixan 2,5 mg and 5 mg Film-coated tablets professional information leaflet below is the property of Viatris South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
